Artemisinin-based combination therapies (ACTs) are the most effective treatment for Plasmodium falciparum infections—the deadliest form of malaria responsible for the vast majority of the estimated 608,000 malaria deaths reported in 2022.

Malaria commodities funders have been hearing about drastic fluctuations in artemisinin prices. This could pose challenges for ACT manufacturers to plan for production costs and ensure stable, affordable prices.

Currently, key global health stakeholders lack a comprehensive understanding of the Chinese artemisinin market structure and dynamics, which limits insights into the price drivers of vegetal artemisinin.

PATH produced this 3-month market landscape to enable the global health community to better understand the Chinese artemisinin market and current price fluctuations and to inform efforts to ensure sufficient and affordable access to ACTs.